Literature DB >> 22658439

Estimation of the optimal brachytherapy utilization rate in the treatment of gynecological cancers and comparison with patterns of care.

Stephen R Thompson1, Geoff P Delaney, Gabriel S Gabriel, Susannah Jacob, Prabir Das, Michael B Barton.   

Abstract

PURPOSE: We aimed to estimate the optimal proportion of all gynecological cancers that should be treated with brachytherapy (BT)-the optimal brachytherapy utilization rate (BTU)-to compare this with actual gynecological BTU and to assess the effects of nonmedical factors on access to BT. METHODS AND MATERIALS: The previously constructed inter/multinational guideline-based peer-reviewed models of optimal BTU for cancers of the uterine cervix, uterine corpus, and vagina were combined to estimate optimal BTU for all gynecological cancers. The robustness of the model was tested by univariate and multivariate sensitivity analyses. The resulting model was applied to New South Wales (NSW), the United States, and Western Europe. Actual BTU was determined for NSW by a retrospective patterns-of-care study of BT; for Western Europe from published reports; and for the United States from Surveillance, Epidemiology, and End Results data. Differences between optimal and actual BTU were assessed. The effect of nonmedical factors on access to BT in NSW were analyzed.
RESULTS: Gynecological BTU was as follows: NSW 28% optimal (95% confidence interval [CI] 26%-33%) compared with 14% actual; United States 30% optimal (95% CI 26%-34%) and 10% actual; and Western Europe 27% optimal (95% CI 25%-32%) and 16% actual. On multivariate analysis, NSW patients were more likely to undergo gynecological BT if residing in Area Health Service equipped with BT (odds ratio 1.76, P=.008) and if residing in socioeconomically disadvantaged postcodes (odds ratio 1.12, P=.05), but remoteness of residence was not significant.
CONCLUSIONS: Gynecological BT is underutilized in NSW, Western Europe, and the United States given evidence-based guidelines. Access to BT equipment in NSW was significantly associated with higher utilization rates. Causes of underutilization elsewhere were undetermined. Our model of optimal BTU can be used as a quality assurance tool, providing an evidence-based benchmark against which actual patterns of practice can be measured. It can also be used to assist in determining the adequacy of BT resource allocation.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22658439     DOI: 10.1016/j.ijrobp.2012.04.014

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

1.  Radiotherapy resources in Africa: an International Atomic Energy Agency update and analysis of projected needs.

Authors:  Shekinah N C Elmore; Alfredo Polo; Jean-Marc Bourque; Yaroslav Pynda; Debbie van der Merwe; Surbhi Grover; Kirsten Hopkins; Eduardo Zubizarreta; May Abdel-Wahab
Journal:  Lancet Oncol       Date:  2021-09       Impact factor: 41.316

2.  Patterns of care study of brachytherapy in New South Wales: malignancies of the uterine corpus.

Authors:  Stephen R Thompson; Geoff P Delaney; Gabriel S Gabriel; Michael B Barton
Journal:  J Contemp Brachytherapy       Date:  2015-06-29

3.  Patterns of care study of brachytherapy in New South Wales: cervical cancer treatment quality depends on caseload.

Authors:  Stephen R Thompson; Geoff P Delaney; Gabriel S Gabriel; Michael B Barton
Journal:  J Contemp Brachytherapy       Date:  2014-04-03

4.  Dosimetric feasibility of stereotactic body radiation therapy as an alternative to brachytherapy for definitive treatment of medically inoperable early stage endometrial cancer.

Authors:  Ryan Jones; Quan Chen; Ryan Best; Bruce Libby; Edwin F Crandley; Timothy N Showalter
Journal:  Radiat Oncol       Date:  2014-07-24       Impact factor: 3.481

5.  A questionnaire-based survey on 3D image-guided brachytherapy for cervical cancer in Japan: advances and obstacles.

Authors:  Tatsuya Ohno; Takafumi Toita; Kayoko Tsujino; Nobue Uchida; Kazuo Hatano; Tetsuo Nishimura; Satoshi Ishikura
Journal:  J Radiat Res       Date:  2015-08-11       Impact factor: 2.724

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.